TY  - JOUR
AU  - Palleis, Carla
AU  - Brendel, Matthias
AU  - Finze, Anika
AU  - Weidinger, Endy
AU  - Bötzel, Kai
AU  - Danek, Adrian
AU  - Beyer, Leonie
AU  - Nitschmann, Alexander
AU  - Kern, Maike
AU  - Biechele, Gloria
AU  - Rauchmann, Boris-Stephan
AU  - Häckert, Jan
AU  - Höllerhage, Matthias
AU  - Stephens, Andrew W.
AU  - Drzezga, Alexander
AU  - Eimeren, Thilo
AU  - Villemagne, Victor L.
AU  - Schildan, Andreas
AU  - Barthel, Henryk
AU  - Patt, Marianne
AU  - Sabri, Osama
AU  - Bartenstein, Peter
AU  - Perneczky, Robert
AU  - Haass, Christian
AU  - Levin, Johannes
AU  - Höglinger, Günter U.
TI  - Cortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes
JO  - Movement disorders
VL  - 36
IS  - 9
SN  - 0885-3185
CY  - New York, NY
PB  - Wiley
M1  - FZJ-2021-05941
SP  - 2104 - 2115
PY  - 2021
AB  - Background: Corticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (~50% of cases) or mixed 3-repeat/4-repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases).Objectives: The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [18 F]PI-2620 in patients with corticobasal syndrome.Methods: Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [18 F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [18 F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [18 F]PI-2620 binding was correlated with clinical and demographic data.Results: Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [18 F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [18 F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [18 F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [18 F]PI-2620 signal reflected contralateral predominance of clinical disease severity.Conclusions: Our data indicate a value of [18 F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [18 F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords: Alzheimer's disease; PET; corticobasal syndrome; four-repeat tauopathies; tau.
LB  - PUB:(DE-HGF)16
C6  - 33951244
UR  - <Go to ISI:>//WOS:000647195800001
DO  - DOI:10.1002/mds.28624
UR  - https://juser.fz-juelich.de/record/904371
ER  -